PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

Oppositions and appeals

We provide support for litigation and other contentious proceedings, including EPO oppositions and appeals.

A granted European patent can be revoked centrally at the EPO in every designated state at once, but only for nine months following grant. Our experienced attorneys act on both sides, clearing patents that stand between you and your market, and defending the patents that are important to your business.

Offensive oppositions

You may need to clear a competitor’s patent from your path to market, or to narrow its scope before launch. We assess quickly whether an opposition is likely to succeed, and how it compares with alternative options including designing around or taking a licence. Where an opposition is the right route, we search for prior art and public prior use, examine entitlement to priority, and craft the novelty, inventive step, sufficiency and added matter attacks strategically to secure the best outcome for your business.

Defensive oppositions

Your own patent may be opposed by a competitor seeking to clear its path to market. We defend it with your commercial position in view, since the claims that survive must continue to cover the product as marketed and its approved label. We build auxiliary request sets around the commercially important claims, advise on experimental and comparative data in support of inventive step, and can advise on strategy for divisional applications.

Freedom to operate

Oppositions usually begin as a freedom-to-operate issue, for example finding a third-party application that would cover your candidate if it grants as filed. We can carry out the freedom-to-operate analysis that identifies these patent applications in the first place so that the families that matter to your pipeline can be monitored, grants that call for a decision are flagged, and further action can be taken whilst there is still time to clear the path.

Third-party observations

Anyone may submit arguments and prior art before the examining division while a patent application is still pending and this can be done anonymously. Used well, observations can be an effective way to narrow a competitor’s claims before grant and can remove the need for an opposition entirely. We advise on whether observations strengthen your position, and how to frame them if they do.

Challenges beyond Europe

EPO oppositions are often the most effective way to challenge a European patent, but they are only one route. Patents can also be challenged after grant in the US, Japan, China and other markets, each with its own procedure, timing and evidence rules. We coordinate these challenges with trusted local attorneys, so that the arguments, evidence and amendments in one forum support your position in the others.

Fractional IP counsel

Our fractional IP counsel model places a named senior patent attorney inside your team as your head of IP, watching competitor grants and the nine-month opposition window, and deciding with you which patents to challenge, which to defend and when.

Why fractional IP counsel for oppositions and appeals? The decision to oppose, or to defend, is a commercial one. Our patent directors have made those calls from inside pharma and biotech companies, so they bring the real-world industry experience that you only get working in-house to deciding which patents matter and when to act. They then work with the experienced opposition attorneys in our team, supported by Albert, rather than starting from scratch as a lone consultant would, or treating the case as a standalone legal exercise as a traditional firm might. Every challenge fits a global strategic approach across the family.

Fractional IP counsel

Whether you are deciding how to deal with a competitor’s newly granted patent, or looking to defend one of your own patents, contact us today to discuss how our experienced attorneys can support you.

Evolve AI

Albert: Validity, oppositions and competitive intelligence

Albert sets out a patent’s data, construes the claims and finds the weak points so that we can get to the analysis quickly.

In pharma, validity nearly always comes down to the data. Albert is a set of modules, one for each question we tend to ask of a patent, whether it belongs to a competitor, a licensing target or one of our own clients. It prepares:

  • Data: each embodiment matched to its effect, the experiments behind it and the claims it supports, with a score for how good the evidence is
  • Basis, support, novelty, inventive step and priority: claim by claim, against the application as filed, the data and the prior art
  • Sequences and Markush formulae: lead sequences checked, generic formulae drawn out, expanded or compared with a real compound
  • Construe: each claim term read against the specification

We use Albert for competitive intelligence, freedom to operate, oppositions and diligence. Albert gets us to a strategic view quickly, and we go deeper only where a particular risk warrants it. More on Albert and Albert Construe.

More about Albert
Albert

Read more

Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image

Lack of clarity by the backdoor: An ambiguity “may simply result in a broader interpretation” (T 0977/25)

  • 4th October 2026
In T 0977/25, a Board of Appeal found that the word “it” in an amended method claim for an e-cigarette cartridge was ambiguous.
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

Claim construction checkpoints: Application as filed versus granted patent (T 0715/24)

  • 16th September 2026
G 1/24 requires that the description must always be “consulted” to interpret a claim. The question remains whether a definition in the description can override an otherwise clear meaning in the claims. In T 0715/24, Bristol-Myers Squibb (BMS) sought to persuade the Board of Appeal that a negative feature, read together with a paragraph of…
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image

G1/25: What are the consequences?

  • 12th September 2026
Following the release of G1/25, questions have been circling as to what the decision means for the pending referral in G 1/26 and what the consequences (good or bad) are for applicants and patentees.
Gold ball-and-stick molecule with one turquoise atom on dark blue, Evolve pharmaceuticals image
Gold ball-and-stick molecule with one turquoise atom on dark blue, Evolve pharmaceuticals image

EPO pharma case law trends 2025: Clinical inventions

  • 26th November 2025
The law in the pharma sector is also constantly evolving. Understanding the case law trends when drafting, prosecuting and defending these cases is therefore paramount. In our second post on EPO pharma case law trends in 2025, we review the most impactful decisions of the year relating to clinical-stage inventions. 
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image

EPO pharma case law trends 2025: Antibodies and biologics

  • 19th November 2025
The science of biologics is rapidly progressing, with the development of ever more complex protein structures, incorporation of molecules into cell therapies and the increasing use of AI-assisted design and in silico modelling. Patent law must respond to these new challenges. What better time to take a look at the trends from the EPO case…
Single cut gold stone glowing turquoise at its heart on dark blue, Evolve abstract article image
Single cut gold stone glowing turquoise at its heart on dark blue, Evolve abstract article image

Patentee’s own post-published data undermines the credibility of their broad cat antibody patent (T 0709/23)

  • 27th October 2025
How early is too early to file a biotech patent? EPO decision T 0709/23 provides a costly answer, demonstrating the fatal risks of claiming a broad therapeutic use before the link between structure, function, and actual effect is truly understood.
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image

The unforgiving gold standard: Why deleting a feature can add matter at the EPO (T 0422/23)

  • 30th September 2025
Addition by subtraction: How deleting a feature from a patent claim can fall foul of the EPO’s unforgiving rules on added matter.
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image

The party’s over: EBA leaves late interveners stranded (G 2/24)

  • 26th September 2025
Can a third party intervener take over a withdrawn appeal at the EPO? The EBA gives a clear ‘No’.
View more Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice